1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020; 92: 418–423.
2. McFee RB. Human pathogen coronaviruses – An overview. Disease-a-Month 66 (2020) 101066.
3. Kesheh MM, Hosseini P, Soltani S, Zandi M. An overview on the seven pathogenic human coronaviruses. Rev Med Virol 2022;32:e2282: 1-13.
4. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends in Microbiology 2016; 24(6): 490-502.
5. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA 1967; 57
(4), 933–40.
6. Abraham T. Twenty-first century plague: The story of SARS. Baltimore, Md. Johns Hopkins University Press. ISBN 0-8018-8124-2. OCLC 57416819, 2005.
7. Khan Ali S, Patrick W. The Next Pandemic (On the front lines against humankind’s gravest dangers). New York: PublicAffairs, 2016.
8. Dünya Sağlık Örgütü, “Dr. Carlo Urbani of the World Health Organization dies of SARS”, https://web.archive.org/web/20170704000323/http://www.who.int/csr/sars/urbani/en/,Ziyaret 30
Aralık 2023.
9. Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using
a novel multiplex real-time PCR method. J Clin Microbiol 2010; 48: 2940–2947.
10. Mohammed Zaki A, Boheemen S, Bestebroer TM, Osterhaus A, Fouchier R. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367: 1814–1820
11. Hijavi B, Abdallat M, Sayadeh A, Alqasrawi S, Haddadin a, Jaarour N, Alsheikh S, Alsanouri T. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospe-
ctive investigation. Eastern Mediterranean Health Journal. 2013; 19(1): 12-18.
12. Zumla A, Hui DS, Periman S. Middle East respiratory syndrome. Lancet 2015; 386: 995–1007.
13. Dünya Sağlık Örgütü, MERS situation update, October 2023, https://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html, Ziyaret 2 Ocak 2024.
14. Dünya Sağlık Örgütü, Coronavirus Disease (COVID-19) pandemic, https://www.who.int/emergencies/diseases/novel-coronavirus-2019, Ziyaret 7 Ocak 2024.
15. Bergmann CC, Silverman RH. COVID‐19: Coronavirus replication, pathogenesis, and therapeutic strategies. Cleve Clin J Med. 2020;87(6):321-327.
16. Tang G, Liu Z, Chen D. Human coronaviruses: Origin, host and receptor. J Clin Virol 2022; 155: 105246.
17. Chen B, Tian EK, He B, Tian L, Han R, Wang S, et all. Overview of lethal human coronaviruses. Signal Transduction and Targeted Therapy 2020; 5: 89
18. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nature Rev Microbiol 2021; 19: 141-154.
19. KLİMUD Pandemi Rehberi, Bölüm 4. COVID-19 Epidemiyolojisi, Candan Çiçek, Sayfa 41-47, 1. Baskı, Ekim 2021, KLİMUD Kaynak No:16, Ankara.
20. Dünya Sağlık Örgütü, Updated working definitions and primary actions for SARS-CoV-2 variants, https://www.who.int/publications/m/item/updated-working-definitions-and-primary-ac-
tions-for–sars-cov-2-variants, Ziyaret 08. 02. 2024
21. Rashedİi R, Samieefar N, Akhlaghdoust M, Mashhadi M, Darzi P, Rezaei N. Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immu-
ne Characteristics. Acta Biomed 2022; 93, N. 1: e2022179
22. Dünya Sağlık Örgütü, Statement on the update of WHO’s working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest. https://www.who.int/news/
item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest, Ziyaret 10 Şubat 2024.
23. Araf Y, Akter F, Tang YD, Fatemi R, Parvez SA, Zheng C, Hossain G. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol
2022;94(5):1825-1832.
24. Dünya Sağlık Örgütü, Updated working definitions and primary actions for SARS-CoV-2 variants, 4 October 2023, https://www.who.int/docs/default-source/coronaviruse/annex1_upda-
ted_working_definitions_17-08-2023.pdf?sfvrsn=2cde3a06_7, Ziyaret, 10 Şubat 2024
25. Dünya Sağlık Örgütü, Varyantların Güncellenmesi https://www.who.int/docs/default-source/coronaviruse/18122023_jn.1_ire_clean.pdf?sfvrsn=6103754a_3, Ziyaret 10 Şubat 2024
26. Essabbar A, Mazouri AS, Boumajdi N, Bendani H, Aanniz T, Mouna O, Lahcen B, Ibrahimi A. Collection 2024 Feb.Temporal Dynamics and Genomic Landscape of SARS-CoV-2 After Four
Years of Evolution. Cureus 2024 Feb 5;16(2): e53654.
27. Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nature Rev Microbiol. 2022; 20: 270-284.
28. Dünya Sağlık Örgütü, Consensus document on the epidemiology of severe acute respiratory syndrome (SARS), Baskı: 17 Mayıs 2003, Ziyaret 26 Şubat 2024.
29. Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, Dhama K, Yatoo MI, D. Katterine Bonilla-Aldana DK, Rodriguez-Morales AJ. SARS-CoV-2, SARS-CoV, and MERS-CoV: a
comparative overview. Le Infezioni in Medicina, 2020; 2: 174-184.
30. Lamers MM, Mykytyn AZ, Breugem TI, Groen N, Knoops K, Schipper D, Acker R, Doel PB, Bestebroer T, Koopman CD, Reusken C, Murao MJ, GeurtsvanKessel CH, Royen ME, Peters PJ,
Zhang J, Haagmans BL. SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium. bioRxiv https://doi.org/10.1101/2022.01.19.476898 (2022).
31. Xie N, Zhang W, Chen J, Tian F, Song J. Clinical Characteristics, Diagnosis, and Therapeutics of COVID-19: A Review. Current Medical Science. 2023; 43: 1066–1074.
32. Mahajan S, Caraballo C, Li SX, Dong Y, Chen L, Huston SK, Srinivasan R, Redlich CA, Ko Aı, Faust JS, Forman H, Krumholz HM. SARS-CoV-2 infection hospitalization rate and infection fatality rate
among the non-congregate population in Connecticut. Am J Med. 2021; 134: 812–816.
33. Dünya Sağlık Örgütü, Clinical management of COVID-19, Living guideline-18 Ağustos 2023, https://iris.who.int/bitstream/handle/10665/372288/WHO-2019-nCoV-clinical-2023.2-eng.
pdf?sequence=1, Ziyaret 29 Şubat 2024.
34. Zhu J, Ji P, Pang J, Zhong Z, li H, He C, Zhang J, Zhao C. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol. 2020 Oct;92(10):1902-1914. doi: 10.1002/jmv.25884.
Epub 2020 Jun 24.
35. Dünya Sağlık Örgütü, Diagnostic testing for SARS-CoV-2. https://iris.who.int/bitstream/handle/10665/334254/WHO-2019-nCoV-laboratory-2020.6-eng.pdf?sequence=1, Ziyaret 06.03.2024
36. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections the state of the art. Emerging Microbes & Infections 2020; 9: 747-756.
37. Hayden MK, Hanson KE, Janet A. Englund JA, Lee MJ, Loeb M, Lee F, Morgan DJ, Patel R, Mikati IKE, Iqneibi S, Alabed F, Amarin JZ, Mansour R, Patel P, Falck-Ytter Y, Morgan RL, Murad
MH, Sultan S, Bhimraj A, Mustafa RA. The Infectious Diseases Society of America Guidelines on the Diagnosis of Coronavirus Disease 2019 (COVID-19): Molecular Diagnostic Testing.
IDSA Guidelines. Clin Infect Dis. 19 December 2023, https://doi.org/10.1093/cid/ciad646.
38. Meumann EM, Robson JMB. Testing for COVID‐19: A 2023 update. Australian Prescriber 2023; 46: 13-17
39. Dünya Sağlık Örgütü, Laboratory biosafety guidance related to SARS-CoV-2 (COVID-19): Interim guidance, 11 March 2024, https://www.who.int/publications/i/item/who-whe-epp-2024.3,
Ziyaret 13 Mart 2024.
40. Centers for Disease Control and Prevention. COVID-19 Treatments and Medications. https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html, Ziyaret
15.03.2024.
41. Dünya Sağlık Örgütü, Therapeutics and COVID-19. https://iris.who.int/bitstream/handle/10665/373975/WHO-2019-nCoV-therapeutics-2023.2-eng.pdf?sequence=1, Living Guideline 10
November 2023, Ziyaret 15.03.2024.
42. DSÖ, Advice for the public: Coronavirus disease (COVID-19), https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public, Ziyaret 19.03.2024.
43. Huguet-Torres A, Castro-Sánchez E, Capitán-Moyano L, Sánchez-Rodríguez C, Bennasar-Veny M and Yáñez AM. Personal protective measures and settings on the risk of SARS-COV-2
community transmission: a case–control study. Front. Public Health 2024; 11:1327082. doi: 10.3389/fpubh.2023.1327082
44. Dünya Sağlık Örgütü, COVID-19 Vaccines with WHO Emergency Use Listing, https://extranet.who.int/prequal/vaccines/covid-19-vaccines-who-emergency-use-listing, Ziyaret 19.03.2024.
45. Kyaw MH, Spinardi J, Zhang L, Lin Oh HM, Srivastava A. Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster
after inactivated SARS-CoV-2 virus vaccines. Human Vaccines & Immunotherapeutics 2023; 19 (1): 1-17.
46. Centers for Disease Control and Prevention. Overview of COVID-19 Vaccines https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/overview-COVID-19-vaccines.html,
Ziyaret 19.03.2024.
47. Jamous YF, Alhomoud DA. The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2. Cureus 2023; 15(9): e45602. DOI 10.7759/cureus.45602.
48. Kayalı GA, Durmaz S, Şahin İR, Akkül B, Durusoy R, Akarca FK, Ulukaya S, Çiçek C. COVID-19 Infection, Vaccination, and Antibody Levels: Investigating Correlations through a Cohort
Study. Vaccines 2023; 11(7): 1258-1270.
49. Faksova K, Walsh D, Jiang Y, Griffin J, Phillips A, Gentile A, et al. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort
study of 99 million vaccinated individuals. Vaccine 30 Ocak 2024; https://doi.org/10.1016/j.vaccine.2024.01.100.
50. Mercadé-Besora N, Li X, Kolde R, Trinh NT, Sanchez-Santos MT, Man WY, Roel E, Reyes C, Delmestri A, Nordeng HME, Uusküla A, Duarte-Salles T, Prats C, Prieto-Alhambra D, Jödicke
AM, Catala M. The role of COVID-19 vaccines in preventing post- COVID-19 thromboembolic and cardiovascular complications. Heart 2024; 0:1–9. doi:10.1136/heartjnl-2023-323483